- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 84
SomaLogic swells series A round to $214m
The Novartis, Nan Fung, iCarbonX, Otsuka and Quest Diagnostics-backed proteomics technology developer has closed the second tranche of the round.
Dec 28, 2020Singleron rings up $30m
Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.
Dec 28, 2020Nio Capital sees Fiture in $20m round
Nio Capital led the Tencent and Bertelsmann Asia Investments-backed home fitness technology developer's series A-plus round.
Dec 28, 2020Magnax pushes ignition on $19.5m round
Magnax raised the cash from investors including automotive parts firm Hirschvogel Automotive with a view of broadening R&D and entering new markets with its EV motor technology.
Dec 24, 2020Neomorph bonds $109m
Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.
Dec 22, 2020Xiangdao Chuxing checks in series A funding
Corporates Alibaba and CATL made strategic investments in SAIC's on-demand ride spinoff, through a $45.9m round preceding a planned geographic expansion.
Dec 19, 2020Corporate venturing deal net: 14-18 December 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Dec 18, 2020Crehana creates space for more series A cash
Salesforce Ventures has taken part in the $17.5m close of the online learning platform developer's series A round, following a $4.5m first tranche early last year.
Dec 18, 2020Daily deal net: December 18, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Dec 18, 2020Neuron23 comes out of stealth with $114m
Biopharmaceutical company Origenis helped form the neurological and immunological disease drug developer, which has revealed series A and B funding.
Dec 18, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


